Nanovector-mediated drug delivery for spinal cord injury treatment

2014 ◽  
Vol 6 (5) ◽  
pp. 506-515 ◽  
Author(s):  
Ilaria Caron ◽  
Simonetta Papa ◽  
Filippo Rossi ◽  
Gianluigi Forloni ◽  
Pietro Veglianese
2020 ◽  
Vol 32 (43) ◽  
pp. 2070325
Author(s):  
Letao Yang ◽  
Brian M. Conley ◽  
Susana R. Cerqueira ◽  
Thanapat Pongkulapa ◽  
Shenqiang Wang ◽  
...  

2012 ◽  
Vol 159 (2) ◽  
pp. 271-280 ◽  
Author(s):  
Giuseppe Perale ◽  
Filippo Rossi ◽  
Marco Santoro ◽  
Marco Peviani ◽  
Simonetta Papa ◽  
...  

2022 ◽  
Vol 13 ◽  
pp. 100177
Author(s):  
Xue Jiang ◽  
Xiaoyao Liu ◽  
Qi Yu ◽  
Wenwen Shen ◽  
Xifan Mei ◽  
...  

Nano Letters ◽  
2018 ◽  
Vol 18 (8) ◽  
pp. 4965-4975 ◽  
Author(s):  
Han Young Kim ◽  
Hemant Kumar ◽  
Min-Jae Jo ◽  
Jonghoon Kim ◽  
Jeong-Kee Yoon ◽  
...  

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Guodong Sun ◽  
Shenghui Zeng ◽  
Xu Liu ◽  
Haishan Shi ◽  
Renwen Zhang ◽  
...  

Abstract Acute inflammation is a central component in the progression of spinal cord injury (SCI). Anti-inflammatory drugs used in the clinic are often administered systemically at high doses, which can paradoxically increase inflammation and result in drug toxicity. A cluster-like mesoporous silica/arctigenin/CAQK composite (MSN-FC@ARC-G) drug delivery system was designed to avoid systemic side effects of high-dose therapy by enabling site-specific drug delivery to the spinal cord. In this nanosystem, mesoporous silica was modified with the FITC fluorescent molecule and CAQK peptides that target brain injury and SCI sites. The size of the nanocarrier was kept at approximately 100 nm to enable penetration of the blood–brain barrier. Arctigenin, a Chinese herbal medicine, was loaded into the nanosystem to reduce inflammation. The in vivo results showed that MSN-FC@ARC-G could attenuate inflammation at the injury site. Behavior and morphology experiments suggested that MSN-FC@ARC-G could diminish local microenvironment damage, especially reducing the expression of interleukin-17 (IL-17) and IL-17-related inflammatory factors, inhibiting the activation of astrocytes, thus protecting neurons and accelerating the recovery of SCI. Our study demonstrated that this novel, silica-based drug delivery system has promising potential for clinical application in SCI therapy.


Neuroscience ◽  
2016 ◽  
Vol 322 ◽  
pp. 377-397 ◽  
Author(s):  
M. Yousefifard ◽  
V. Rahimi-Movaghar ◽  
F. Nasirinezhad ◽  
M. Baikpour ◽  
S. Safari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document